(IN BRIEF) In early 2024, Europe's medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like…
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for…
(IN BRIEF) AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review…
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO)…
(IN BRIEF) Researchers at the University of Liverpool, in collaboration with Janssen Pharmaceutica, have made significant progress in using blood…
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer…
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010…
(PRESS RELEASE) FREIBURG, Germany, 1-Jul-2021 — /EuropaWire/ — Prostate cancer is the second most common cancer. According to the American…
(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food…
uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of…
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic…
This year's Swiss Aerosol Award goes to Maria Muñoz. The Empa researcher investigated the emission behavior of so-called GDI engines…
BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its…
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung…
NAVIGATE Study Assesses Impact of Minimally Invasive Technology to Aid in Early Diagnosis and Treatment of Lung Cancer DUBLIN, 14-Mar-2016…
• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression…
BASEL, 14-12-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) granted…
Second FDA Breakthrough Therapy Designation for MPDL3280A following bladder cancer in 2014 BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO,…
Marks GSK’s fourth Breakthrough Therapy designation London, UK, 17-1-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) announced today that the U.S.…
New test expands cancer diagnostics portfolio and strengthens Roche Diagnostics’ comprehensive tumour marker menu 19-7-2013 — /europawire.eu/ — Roche (SIX: RO,…